USP35 and lung carcinoma: USP35 knockdown promotes ferroptosis and increases the sensitivity of lung cancer cells to paclitaxel and cisplatin.144 Conversely, overexpression of USP35 facilitates lung cancer cell growth and tumor progression by reducing Erastin/RSL3-triggered ferroptosis.